Cargando…
Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites
Reovirus is an oncolytic virus (OV), which acts by both direct tumor cell killing and priming of antitumor immunity. A major obstacle for effective oncolytic virotherapy is effective delivery of OV to tumor cells. Ovarian cancer is often confined to the peritoneal cavity and therefore i.p. delivery...
Autores principales: | Jennings, VA, Ilett, EJ, Scott, KJ, West, EJ, Vile, R, Pandha, H, Harrington, K, Young, A, Hall, GD, Coffey, M, Selby, P, Errington-Mais, F, Melcher, AA |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321045/ https://www.ncbi.nlm.nih.gov/pubmed/23982804 http://dx.doi.org/10.1002/ijc.28450 |
Ejemplares similares
-
Past, Present and Future of Oncolytic Reovirus
por: Müller, Louise, et al.
Publicado: (2020) -
Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming
por: Steele, Lynette, et al.
Publicado: (2011) -
Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics
por: Harrington, K.J., et al.
Publicado: (2010) -
Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer
por: Samson, Adel, et al.
Publicado: (2018) -
Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia
por: Parrish, C, et al.
Publicado: (2015)